Pacific Edge continues to make progress commercialising its suite of bladder cancer diagnostics products, with three tests currently available in the US market. An uplift in sales is expected as TRICARE and the Veterans Administration (VA) are under contract, although the exact timing of a sales ramp is unknown. In addition, the company’s discussions with Kaiser Permanente are nearing a final decision and progress has been made with achieving inclusion in the local coverage determinatio
09 Jan 2018
Pacific Edge - Anticipating commercial growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pacific Edge - Anticipating commercial growth
Pacific Edge Limited (PEB:NZE) | 0 0 0.0% | Mkt Cap: 186.5m
- Published:
09 Jan 2018 -
Author:
Maxim Jacobs -
Pages:
12
Pacific Edge continues to make progress commercialising its suite of bladder cancer diagnostics products, with three tests currently available in the US market. An uplift in sales is expected as TRICARE and the Veterans Administration (VA) are under contract, although the exact timing of a sales ramp is unknown. In addition, the company’s discussions with Kaiser Permanente are nearing a final decision and progress has been made with achieving inclusion in the local coverage determinatio